180 related articles for article (PubMed ID: 11403227)
1. Interferon beta1a treatment modulates TH1 expression in gammadelta + T cells from relapsing-remitting multiple sclerosis patients.
Elliott CL; El-Touny SY; Filipi ML; Healey KM; Leuschen MP
J Clin Immunol; 2001 May; 21(3):200-9. PubMed ID: 11403227
[TBL] [Abstract][Full Text] [Related]
2. Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment.
Franciotta D; Zardini E; Bergamaschi R; Andreoni L; Cosi V
J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):123-6. PubMed ID: 12486283
[TBL] [Abstract][Full Text] [Related]
3. IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines.
Sega S; Wraber B; Mesec A; Horvat A; Ihan A
Clin Neurol Neurosurg; 2004 Jun; 106(3):255-8. PubMed ID: 15177779
[TBL] [Abstract][Full Text] [Related]
4. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
5. Modulatory effect of celastrol on Th1/Th2 cytokines profile, TLR2 and CD3+ T-lymphocyte expression in a relapsing-remitting model of multiple sclerosis in rats.
Abdin AA; Hasby EA
Eur J Pharmacol; 2014 Nov; 742():102-12. PubMed ID: 25218987
[TBL] [Abstract][Full Text] [Related]
6. Long-term use of interferon-β in multiple sclerosis increases Vδ1
Maimaitijiang G; Watanabe M; Shinoda K; Isobe N; Nakamura Y; Masaki K; Matsushita T; Yoshikai Y; Kira JI
J Neuroinflammation; 2019 Sep; 16(1):179. PubMed ID: 31519178
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Effects of Sodium Benzoate on Th1/Th2 Deviation in Patients with Multiple Sclerosis.
Rezaei N; Amirghofran Z; Nikseresht A; Ashjazade N; Zoghi S; Tahvili S; Kamali-Sarvestani E
Immunol Invest; 2016 Oct; 45(7):679-91. PubMed ID: 27611715
[TBL] [Abstract][Full Text] [Related]
8. Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients.
Wu Q; Wang Q; Mao G; Dowling CA; Lundy SK; Mao-Draayer Y
J Immunol; 2017 Apr; 198(8):3069-3080. PubMed ID: 28258191
[TBL] [Abstract][Full Text] [Related]
9. TH1/TH2,3 imbalance due to cytokine-producing NK, gammadelta T and NK-gammadelta T cells in murine pregnancy decidua in success or failure of pregnancy.
Clark DA; Croitoru K
Am J Reprod Immunol; 2001 May; 45(5):257-65. PubMed ID: 11432400
[TBL] [Abstract][Full Text] [Related]
10. IFNbeta-1a treatment and reestablishment of Th1 regulation in MS patients: dose effects.
Pellegrini P; Totaro R; Contasta I; Berghella AM; Russo T; Carolei A; Adorno D
Clin Neuropharmacol; 2004; 27(6):258-69. PubMed ID: 15613929
[TBL] [Abstract][Full Text] [Related]
11. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
[TBL] [Abstract][Full Text] [Related]
12. Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
Nischwitz S; Faber H; Sämann PG; Domingues HS; Krishnamoorthy G; Knop M; Müller-Sarnowski F; Yassouridis A; Weber F
Acta Neurol Scand; 2014 Jul; 130(1):46-52. PubMed ID: 24571587
[TBL] [Abstract][Full Text] [Related]
13. Regulation by cytokines (IL-12, IL-15, IL-4 and IL-10) of the Vgamma9Vdelta2 T cell response to mycobacterial phosphoantigens in responder and anergic HIV-infected persons.
Boullier S; Poquet Y; Debord T; Fournie JJ; Gougeon ML
Eur J Immunol; 1999 Jan; 29(1):90-9. PubMed ID: 9933090
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory effects of IFN-beta1a treatment alone or associated with pentoxifylline in patients with relapsing-remitting multiple sclerosis (RRMS).
Pede PD; Visintini D; Telera A; Cucurachi L; Campanini C; Immovilli P; Vescovini R; Sansoni P
J Interferon Cytokine Res; 2005 Aug; 25(8):485-9. PubMed ID: 16108731
[TBL] [Abstract][Full Text] [Related]
15. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
Hamamcioglu K; Reder AT
Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
[TBL] [Abstract][Full Text] [Related]
16. STAT3-silenced human dendritic cells have an enhanced ability to prime IFNγ production by both αβ and γδ T lymphocytes.
Sanseverino I; Purificato C; Varano B; Conti L; Gessani S; Gauzzi MC
Immunobiology; 2014 Jul; 219(7):503-11. PubMed ID: 24674241
[TBL] [Abstract][Full Text] [Related]
17. Immunomonitoring measures in relapsing-remitting multiple sclerosis.
Matsui M; Araya SI; Wang HY; Matsushima K; Saida T
J Neuroimmunol; 2004 Mar; 148(1-2):192-9. PubMed ID: 14975601
[TBL] [Abstract][Full Text] [Related]
18. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
Axtell RC; de Jong BA; Boniface K; van der Voort LF; Bhat R; De Sarno P; Naves R; Han M; Zhong F; Castellanos JG; Mair R; Christakos A; Kolkowitz I; Katz L; Killestein J; Polman CH; de Waal Malefyt R; Steinman L; Raman C
Nat Med; 2010 Apr; 16(4):406-12. PubMed ID: 20348925
[TBL] [Abstract][Full Text] [Related]
19. Selective suppression of chemokine receptor CXCR3 expression by interferon-beta1a in multiple sclerosis.
Sørensen TL; Sellebjerg F
Mult Scler; 2002 Apr; 8(2):104-7. PubMed ID: 11990865
[TBL] [Abstract][Full Text] [Related]
20. Lymphocyte calcium influx kinetics in multiple sclerosis treated without or with interferon β.
Toldi G; Folyovich A; Simon Z; Zsiga K; Kaposi A; Mészáros G; Tulassay T; Vásárhelyi B
J Neuroimmunol; 2011 Aug; 237(1-2):80-6. PubMed ID: 21764463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
